• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540) in the treatment of bronchogenic carcinoma.

作者信息

Cavalli F, Hasler E, Ryssel H J, Sonntag R W, Brunner K W

出版信息

Tumori. 1977 Mar-Apr;63(2):169-73. doi: 10.1177/030089167706300207.

DOI:10.1177/030089167706300207
PMID:898287
Abstract

Thirty patients with bronchogenic carcinoma were treated with an 8-week induction therapy consisting of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540). Those who achieved objective remission of tumor stabilization were then placed on an intermittent treatment schedule with the same drugs. Of the 30 patients, 17 had an objective response, 5 remained without change, and 8 progressed. Responses were more frequent among anaplastic (13/19) than epidermoid or adenocarcinoma (4/11). The toxicity consisted mainly of leucopenia, thrombopenia, alopecia, nausea and vomiting. The implications of these findings in the planning of further chemotherapeutic programs are discussed.

摘要

相似文献

1
A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540) in the treatment of bronchogenic carcinoma.
Tumori. 1977 Mar-Apr;63(2):169-73. doi: 10.1177/030089167706300207.
2
[VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
Schweiz Med Wochenschr. 1977 Jul 2;107(26):912-5.
3
Combination chemotherapy with methyl-CCNU (NSC-95441), cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and bleomycin (NSC-125066) in advanced bronchogenic carcinoma.
Cancer Lett. 1975 Nov;1(2):97-102. doi: 10.1016/s0304-3835(75)95630-x.
4
Oral VP-16-213 in advanced bronchogenic carcinoma and toxic effects when combined with methotrexate.口服VP - 16 - 213治疗晚期支气管癌及其与甲氨蝶呤联合应用时的毒性作用。
Thorax. 1981 Jun;36(6):462-4. doi: 10.1136/thx.36.6.462.
5
[Experiences with VP-16 in combination with cyclophosphamide or adriamycin in the anaplastic, predominantly small cell bronchogenic carcinoma].
Schweiz Med Wochenschr. 1979 Jun 2;109(22):841-4.
6
VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.VP16 - 213与环磷酰胺治疗非燕麦细胞支气管源性癌
Cancer Chemother Pharmacol. 1982;7(2-3):209-10. doi: 10.1007/BF00254551.
7
Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristine.采用包括甲氨蝶呤、环磷酰胺、丙卡巴肼和长春新碱的同步或序贯联合化疗方案治疗支气管源性癌。
Cancer. 1976 Dec;38(6):2208-16. doi: 10.1002/1097-0142(197612)38:6<2208::aid-cncr2820380603>3.0.co;2-h.
8
VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.
Cancer Treat Rep. 1976 Jul;60(7):949-51.
9
Chemotherapy in bronchogenic carcinoma.
Ann Clin Res. 1977 Feb;9(1):12-4.
10
Intensive combined chemotherapy and radiotherapy in patients with nonresectable bronchogenic carcinoma.不可切除支气管源性癌患者的强化联合化疗与放疗
Cancer. 1972 Aug;30(2):315-24. doi: 10.1002/1097-0142(197208)30:2<315::aid-cncr2820300202>3.0.co;2-e.

引用本文的文献

1
Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC).
Cancer Chemother Pharmacol. 1982;7(2-3):205-7. doi: 10.1007/BF00254550.
2
Current development of podophyllotoxins.鬼臼毒素的当前发展情况。
Cancer Chemother Pharmacol. 1982;7(2-3):93-8. doi: 10.1007/BF00254528.